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OBJECTIVE: To assess the cost-effectiveness of the use of telm-
isartan (angiotensin-II-recepter blocker, ARB) in patients with
type 2 diabetes and microalbuminuria in Japan. METHODS: We
developed the life-time Markov model that predicts the progres-
sion of diabetic nephropathy. Probabilities of disease progression
were taken from the results of INNOVATION study, which was
the ﬁrst large-scale clinical study to investigate prevention of
overt diabetic nephropathy using an ARB in normotensive and
hypertensive Japanese patients with type 2 diabetes. Sixty-two
year-old Japanese male patients with type 2 diabetes and microal-
buminuria were chosen as the model cases for this analysis. Three
management strategies were compared: 1) use of telmisartan at
the dose of 80 mg daily (T80); 2) use of telmisartan at the dose
of 40 mg daily (T40); and 3) no ARB treatment (control). Payers’
perspective was considered to estimate the costs. The costs for
laboratory tests and pharmaceuticals were obtained from the
National Price List of 2007. The cost of dialysis was derived from
a published article. Quality-adjusted life years (QALYs) was used
to describe the health outcomes. Discounting for both the future
cost and the health outcome was performed at an annual rate of
3%. RESULTS: As compared with the expenditure in the control
group, a projected saving of 120 million yen and 490 million yen,
respectively, was estimated for every 1000 patients on T80 and
T40. T80 added 2870 QALYs, whereas T40 added 1760 QALYs
in 1000 patients. The incremental cost-effectiveness ratio for T80
as compared with that for T40 was 330,395 per QALY gained.
T80 was considered to be cost-effective as compared with T40
and no ARB treatment under a wide range of plausible assump-
tions. CONCLUSION: Use of telmisartan at the dose of 80 mg
daily in male patients with type 2 diabetes and microalbuminuria
appeared to be a cost-effective treatment in Japan.
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OBJECTIVE: The aim of this study was to assess the incremental
cost per quality-adjusted life year of exenatide versus insulin
glargine when added to oral therapy for patients with poorly
controlled type 2 diabetes from the Canadian health care per-
spective. METHODS: Costs and quality-adjusted life years
(QALYs) were modelled for ﬁfty years using the CORE Diabetes
Model, a validated and peer reviewed computer simulation
model. The model simulates the progression of diabetes related
complications based on data from the published literature.
Analyses were conducted for a cohort of patients with the same
characteristics as those participating in a randomized controlled
trial comparing exenatide to insulin glargine. Progression was
modiﬁed by the treatment effects observed in the clinical trial.
Costs and QALYs were derived by weighting events by published
utility values and Canadian speciﬁc costs for 2007. Costs and
QALYs were discounted at 5% as per Canadian guidelines.
Extensive sensitivity analyses were conducted relating to all
treatment effects including the impact on weight. In addition,
probabilistic sensitivity analysis assessed the probability
that treatments were cost-effective given the available data.
RESULTS: Exenatide was associated with higher lifetime
costs per patient than insulin glargine (CDN$57,400 versus
CDN$44,900), but with higher expected QALYs (5.68 versus
5.33) at a cost per QALY gained of CDN$36,300. Results were
most sensitive to changes in the impact of treatment on weight:
when assuming no reduction in weight with exenatide, the incre-
mental cost per QALY was greater than CDN$50,000. The
probabilistic analysis found that the probability that exenatide is
cost effective (assuming a threshold of CDN$50,000) is 75%.
CONCLUSION: Based on previous decisions relating to the
funding of treatments for chronic therapy in Canada, these
results demonstrate that exenatide may represent a cost-effective
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OBJECTIVE: Indirect costs due to lost productivity account for
an estimated one-third of the total economic burden associated
with diabetes. Little is known about the relative contributions of
type 1 (T1DM) and type 2 diabetes (T2DM) to indirect costs.
This study quantiﬁes and compares the amount of work loss
incurred by individuals with T1DM and T2DM. METHODS:
Productivity data (Thomson MarketScan) from a database of
the commercially-insured was used to identify individuals for
analysis. Patients with diabetes in the pre-period with at least
two claims for an antidiabetic drug in 2005 and 24 months of
continuous enrollment were selected. Control groups of persons
without diabetes were selected using propensity score matching.
Total number of days lost due to paid absence and short-term
disability (STD), conditional upon work loss, were evaluated.
Associated costs were estimated using an average hourly wage
and beneﬁt rate of $30.00. RESULTS: A total of 877 patients
with T1DM and 7033 patients with T2DM were identiﬁed.
Patients with T1DM who incurred work loss missed an average
of 25.4 days due to absence and 45.6 days due to STD, valued at
$6108 and $7659, respectively. Patients with T2DM with work
loss missed an average of 29.7 days due to absence and 46.5 days
due to STD, valued at $7136 and $7812, respectively. Patients
with T1DM missed signiﬁcantly more days due to STD than did
their matched controls (45.6 vs. 37.5 days) (p < 0.0001); patients
with T2DM had signiﬁcantly more absence days than their
matched controls 29.7 vs. 27.7 days) (p < 0.0001). CONCLU-
SION: Patients with T2DM incurred more work loss than
patients with T1DM. Patients with T1DM incurred more work
loss due to STD, but not to paid absence, than did their
non-diabetic controls, while patients with T2DM had more work
loss due to paid absence, but not STD, than did their matched
controls.
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